Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies

Christiana Mo; Michelle Sterpi; Hyein Jeon; Fernand Bteich

doi:10.3390/cancers16162854

Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies

Christiana Mo, Michelle Sterpi, Hyein Jeon, Fernand Bteich

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Human epidermal growth factor 2 (HER2) is a tyrosine kinase receptor that interacts with multiple signaling pathways related to cellular growth and proliferation. Overexpression or amplification of HER2 is linked to various malignancies, and there have been decades of research dedicated to targeting HER2. Despite the landmark ToGA trial, progress in HER2-positive gastrointestinal malignancies has been hampered by drug resistance. This review examines current HER2 expression patterns and therapies for gastroesophageal, colorectal, biliary tract, and small bowel cancers, while dissecting potential resistance mechanisms that limit treatment effectiveness.

Original language	English
Article number	2854
Journal	Cancers
Volume	16
Issue number	16
DOIs	https://doi.org/10.3390/cancers16162854
State	Published - Aug 2024
Externally published	Yes

Keywords

cancer therapeutics
colorectal cancer
gastro/gastroesophageal cancer
HER2
resistance

Access to Document

10.3390/cancers16162854

Cite this

@article{f70a38a93f6443c8b8dcfdbc781a7f0d,

title = "Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies",

abstract = "Human epidermal growth factor 2 (HER2) is a tyrosine kinase receptor that interacts with multiple signaling pathways related to cellular growth and proliferation. Overexpression or amplification of HER2 is linked to various malignancies, and there have been decades of research dedicated to targeting HER2. Despite the landmark ToGA trial, progress in HER2-positive gastrointestinal malignancies has been hampered by drug resistance. This review examines current HER2 expression patterns and therapies for gastroesophageal, colorectal, biliary tract, and small bowel cancers, while dissecting potential resistance mechanisms that limit treatment effectiveness.",

keywords = "cancer therapeutics, colorectal cancer, gastro/gastroesophageal cancer, HER2, resistance",

author = "Christiana Mo and Michelle Sterpi and Hyein Jeon and Fernand Bteich",

note = "Publisher Copyright: {\textcopyright} 2024 by the authors.",

year = "2024",

month = aug,

doi = "10.3390/cancers16162854",

language = "English",

volume = "16",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "16",

}

TY - JOUR

T1 - Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies

AU - Mo, Christiana

AU - Sterpi, Michelle

AU - Jeon, Hyein

AU - Bteich, Fernand

PY - 2024/8

Y1 - 2024/8

N2 - Human epidermal growth factor 2 (HER2) is a tyrosine kinase receptor that interacts with multiple signaling pathways related to cellular growth and proliferation. Overexpression or amplification of HER2 is linked to various malignancies, and there have been decades of research dedicated to targeting HER2. Despite the landmark ToGA trial, progress in HER2-positive gastrointestinal malignancies has been hampered by drug resistance. This review examines current HER2 expression patterns and therapies for gastroesophageal, colorectal, biliary tract, and small bowel cancers, while dissecting potential resistance mechanisms that limit treatment effectiveness.

AB - Human epidermal growth factor 2 (HER2) is a tyrosine kinase receptor that interacts with multiple signaling pathways related to cellular growth and proliferation. Overexpression or amplification of HER2 is linked to various malignancies, and there have been decades of research dedicated to targeting HER2. Despite the landmark ToGA trial, progress in HER2-positive gastrointestinal malignancies has been hampered by drug resistance. This review examines current HER2 expression patterns and therapies for gastroesophageal, colorectal, biliary tract, and small bowel cancers, while dissecting potential resistance mechanisms that limit treatment effectiveness.

KW - cancer therapeutics

KW - colorectal cancer

KW - gastro/gastroesophageal cancer

KW - HER2

KW - resistance

UR - http://www.scopus.com/inward/record.url?scp=85202498849&partnerID=8YFLogxK

U2 - 10.3390/cancers16162854

DO - 10.3390/cancers16162854

M3 - Review article

AN - SCOPUS:85202498849

SN - 2072-6694

VL - 16

JO - Cancers

JF - Cancers

IS - 16

M1 - 2854

ER -

Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies

Abstract

Keywords

Access to Document

Fingerprint

Cite this